Stewart Goldman, MD | Phoenix Children ...

Dr. Stewart Goldman, MD

Claim this profile

Lurie Children's Hospital-Chicago

Expert in Brain Tumor
Studies Diffuse Intrinsic Pontine Glioma
13 reported clinical trials
26 drugs studied

Area of expertise

1

Brain Tumor

Global Leader

Stewart Goldman, MD has run 11 trials for Brain Tumor. Some of their research focus areas include:

H3.3K27M positive
IDH positive
H3F3A
2

Diffuse Intrinsic Pontine Glioma

Stewart Goldman, MD has run 5 trials for Diffuse Intrinsic Pontine Glioma. Some of their research focus areas include:

H3.3K27M positive
H3F3A
HLA-A positive

Affiliated Hospitals

Image of trial facility.

Lurie Children's Hospital-Chicago

Image of trial facility.

Ann & Robert H Lurie Children's Hospital Of Chicago

Clinical Trials Stewart Goldman, MD is currently running

Image of trial facility.

PARP Inhibitor + Temozolomide

for Brain Cancer

This trial studies the safety and best dose of BGB-290 and temozolomide in treating young people with a specific type of brain tumor. BGB-290 blocks enzymes needed for tumor growth, while temozolomide kills or stops cancer cells from growing. The goal is to find out if this combination works better for these patients.

Recruiting

1 award

Phase 1

Image of trial facility.

Antiangiogenic Therapy

for Pediatric Brain Cancer

Patients with relapsed medulloblastoma, ependymoma and ATRT have a very poor prognosis whether treated with conventional chemotherapy, high-dose chemotherapy with stem cell rescue, irradiation or combinations of these modalities. Antiangiogenetic therapy has emerged as new treatment option in solid malignancies. The frequent, metronomic schedule targets both proliferating tumor cells and endothelial cells, and minimizes toxicity. In this study the investigators will evaluate the use of biweekly intravenous bevacizumab in combination with five oral drugs (thalidomide, celecoxib, fenofibrate, and alternating cycles of daily low-dose oral etoposide and cyclophosphamide), augmented with alternating courses of intrathecal etoposide and cytarabine. The aim of the study is to extend therapy options for children with recurrent or progressive medulloblastoma, ependymoma and ATRT, for whom no known curative therapy exists, by prolonging survival while maintaining good quality of life. The primary objective of the MEMMAT trial is to evaluate the activity of this multidrug antiangiogenic approach in these heavily pretreated children and young adults. Additionally, progression-free survival (PFS), overall survival (OS), as well as feasibility and toxicity will be examined.

Recruiting

1 award

Phase 2

More about Stewart Goldman, MD

Clinical Trial Related

9 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Stewart Goldman, MD has experience with

  • Optune System
  • BGB-290
  • Temozolomide
  • Nivolumab
  • K27M Peptide
  • CX-4945

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Stewart Goldman, MD specialize in?

Is Stewart Goldman, MD currently recruiting for clinical trials?

Are there any treatments that Stewart Goldman, MD has studied deeply?

What is the best way to schedule an appointment with Stewart Goldman, MD?

What is the office address of Stewart Goldman, MD?

Is there any support for travel costs?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security